

## TEGOSOFT® APS

Very high polar cosmetic oil with solubilizing properties

- Emollient with a pleasant skin feel
- High ability to solve lipophilic active ingredients and perfume oils
- Vegetable-based

Personal Care

## INCI Name (PCPC Name)

PPG-11 Stearyl Ether

### Chemical and physical properties (not part of specifications)

Form	liquid
------	--------

### Further product information (not part of specifications)

Viscosity at 25 °C according to Höppler (mPas)	approx. 76
Surface tension at 25 °C according to ring method (mN/m)	approx. 30
Spreadability	medium spreading
Polarity	very high polarity
Pour point following DIN ISO 3016 (°C)	approx. 0

### Properties

- Very high polar and viscous cosmetic oil
- Good solubilizer
- Miscible with other cosmetic oils and fats
- Good skin conditioning properties and pleasant after feel on the skin

### Application

TEGOSOFT® APS is especially suitable as an emollient for:

- O/W Emulsions
- Roll-on Antiperspirant
- Colognes and Fragrances
- Bath Oils

## Packaging

772 kg pallet (4 x 193 kg drum)

## Hazardous goods classification

Information concerning

- classification and labelling according to regulations for transport and for dangerous substances
- protective measures for storage and handling
- measures in accidents and fires
- toxicity and ecological effects

is given in our material safety data sheets.

## Guideline Formulations

O/W Antiperspirant Roll On Ma 39/01	
<b>Phase A</b>	
TEGO® Alkanol S 2 Pellets (Steareth-2)	4.0%
TEGO® Alkanol S 20 P (Steareth-20)	2.2%
TEGOSOFT® M (Isopropyl Myristate)	1.0%
TEGOSOFT® APS	4.7%
<b>Phase B</b>	
Aluminum Zirconium Trichlorohydrate GLY (Rezal 33G Solution, Reheis)	63.0%
Water	25.1%
<b>Phase Z</b>	
Preservative, Perfume	q.s.
<b>Preparation:</b>	
1. Heat phase A and B separately to approx. 65 °C.	
2. Add phase A to 85 % slowly to phase B with stirring.	
3. Homogenize slowly for 1 - 4 minutes while cooling to 50 °C.	
4. Add the remaining 15 % of phase B to the batch with overhead mixing and continue mixing until homogeneous.	

<b>Moisturizing Body Cream</b> F 77/00-2	
<b>Phase A</b>	
ABIL® Care 85 (Bis-PEG/PPG-16/16 PEG/PPG-16/16 Dimethicone; Caprylic/Capric Triglyceride)	1.0%
TEGINACID® C (Cetareth-25)	0.5%
TEGIN® M Pellets (Glyceryl Stearate)	4.5%
TEGO® Alkanol 18 (Stearyl Alcohol)	1.5%
TEGOSOFT® APS	2.5%
TEGOSOFT® liquid (Cetearyl Ethylhexanoate)	2.5%
Tocopheryl Acetate	0.5%
<b>Phase B</b>	
TEGOSOFT® PSE 141 G (Sucrose Stearate)	3.0%
Glycerin	2.0%
Panthenol	0.5%
Water	80.5%
<b>Phase C</b>	
TEGO® Carbomer 134 (Carbomer)	0.2%
TEGOSOFT® liquid (Cetearyl Ethylhexanoate)	0.8%
<b>Phase D</b>	
Sodium Hydroxide (10% in water)	q.s.
<b>Phase Z</b>	
Preservative, Perfume	q.s.
<b>Preparation:</b>	
<ol style="list-style-type: none"> <li>1. Heat phase A and B separately to approx. 80 °C.</li> <li>2. Add phase A to phase B with stirring.<sup>1)</sup></li> <li>3. Homogenize.</li> <li>4. Cool with gentle stirring to approx. 60 °C and add phase C.</li> <li>5. Homogenize for a short time.</li> <li>6. Cool with gentle stirring and add phase D below 40 °C.</li> </ol>	
<sup>1)</sup> <b>Important:</b> If phase A has to be charged into the vessel first, phase B must be added <b>without stirring</b> .	

This information and all further technical advice is based on our present knowledge and experience. However, it implies no liability or other legal responsibility on our part, including with regard to existing third party intellectual property rights, especially patent rights. In particular, no warranty, whether express or implied, or guarantee of product properties in the legal sense is intended or implied. We reserve the right to make any changes according to technological progress or further developments.

The customer is not released from the obligation to conduct careful inspection and testing of incoming goods. Performance of the product described herein should be verified by testing, which should be carried out only by qualified experts in the sole responsibility of a customer. Reference to trade names used by other companies is neither a recommendation, nor does it imply that similar products could not be used.  
(Status: April, 2008)